Fluridil
Topilutamide · Eucapil · BP-766
Last updated
At a glance
Overview
What Fluridil Actually Is#
Fluridil — sold commercially as Eucapil and also called topilutamide — is the only topical antiandrogen with a peer-reviewed, placebo-controlled human trial showing meaningful anagen-ratio improvement and zero detectable systemic exposure. That combination is rare. RU58841 has stronger anecdotal regrowth data but no controlled human safety trial; pyrilutamide has middling clinical evidence; topical finasteride works but still suppresses scalp DHT systemically in most users. Fluridil is the clean, boring, well-documented option that quietly does its job at the follicle and disappears the moment it touches blood.
The mechanism is what makes it interesting to the looksmaxxing and on-cycle hair-retention community. Rather than competing with DHT at the androgen receptor, fluridil downregulates AR protein expression locally in the scalp — ~95% reduction in AR on Western blot in LNCaP cells at 10 μM. Because the molecule was rationally designed to hydrolyze on contact with water, any fraction that reaches circulation fragments within minutes into inactive metabolites. No measurable serum levels, no HPTA effects, no libido or erectile changes in the 12-month trial, no PCT, no bloodwork follow-up.
"Neither fluridil nor its hydrolytic product BP-34 could be detected in the serum at baseline or at any time during the 90-day treatment period with 2% fluridil applied topically." — Sovak et al., Dermatologic Surgery (2002)
That profile is why the compound earned its niche: a topical AR-side option that stacks cleanly on top of finasteride + minoxidil, slots into an on-cycle scalp-defense rotation alongside RU58841 or pyrilutamide without compounding systemic antiandrogen load, and remains usable by guys who refuse oral 5-AR inhibition entirely. The trade-off — and it's a real one — is that fluridil is a retention and mild-thickening compound, not a Norwood-reverser. The sections below cover the mechanism in detail, the 2% Eucapil protocol and community-compounded higher concentrations, stacking with finasteride / minoxidil / microneedling / topical AR antagonists, on-cycle use during AAS, side-effect profile, and the application mistakes (chiefly: wet scalp) that cause most "fluridil didn't work for me" reports.
How Fluridil works
Topical Androgen Receptor Suppression#
Fluridil is a non-steroidal anti-androgen that works by downregulating androgen receptor protein expression in scalp tissue rather than competing with DHT for the receptor binding site. This is mechanistically distinct from flutamide, bicalutamide, or RU58841, which occupy the receptor competitively. Fluridil reduces the absolute quantity of AR protein available to be activated — when AR is gone, DHT has nothing to signal through, and the follicle-miniaturization cascade of androgenetic alopecia stalls out.
"At 10 μM fluridil, AR protein in LNCaP cells was reduced by approximately 95% on Western blot after 48 h exposure, indicating strong AR suppressive activity." — Seligson AL et al., Drug Development Research, 2003
For the user, the practical consequence is retention and modest thickening of existing terminal hairs in the affected zones, with anagen ratio shifting upward over 9–12 months of consistent application. It is a holding-line drug, not a Norwood-reverser.
Hydrolytic Self-Destruction (Zero Systemic Exposure by Design)#
The defining feature of fluridil is that it was engineered to fall apart the moment it encounters water. The molecule is highly lipophilic and partitions readily into the stratum corneum and follicle, but any fraction that reaches the aqueous environment of blood or dermis fragments at its amide bond into BP-34 (an inactive arylpropanamide) plus trifluoroacetic acid. This is why the vehicle must be anhydrous isopropanol and why application demands a fully dry scalp — water on the surface destroys the active before it can deposit intra-follicularly.
"Neither fluridil nor its hydrolytic product BP-34 could be detected in the serum at baseline or at any time during the 90-day treatment period with 2% fluridil applied topically." — Sovak M et al., Dermatologic Surgery, 2002
For physique-focused users this is the headline feature: no HPTA suppression, no libido hit in controlled data, no interaction with AAS or SARMs, no PCT consideration. The mechanism is locked to the scalp by chemistry, not by hopeful dosing.
Local Metabolism and the Sexual Side-Effect Profile#
Because fluridil is destroyed in situ rather than being cleared hepatically or renally, it is effectively absent from the systemic compartment. This is the mechanistic reason it does not produce the libido, erectile, or mood signals associated with oral finasteride or dutasteride — there is no circulating drug to act on receptors outside the follicle.
"Fluridil's mechanism is unique among topical agents in that it acts by suppressing androgen receptor expression, and its use is associated with minimal side effects due to its local metabolism." — Kelly Y, Blanco A, Tosti A, Drugs, 2016
This makes fluridil the cleanest option in the topical AR-active category for users who refuse oral 5-AR inhibition over PFS concerns, fertility planning, or simple risk-aversion. It is weaker than RU58841 or pyrilutamide on regrowth signal, but its safety credential is the only one of the three with placebo-controlled human data behind it.
Anagen Ratio and Follicle-Cycle Restoration#
The downstream phenotype of sustained AR suppression at the dermal papilla is a measurable increase in the anagen-to-telogen ratio — more follicles in the active growth phase, fewer in the shedding/resting phase. In the pivotal trial, phototrichogram analysis showed anagen rising from ~76% to ~85–89% over 9 months of nightly 2% application, with vertex and frontal scalp both responding.
"Fluridil has demonstrated efficacy in male pattern hair loss, with studies reporting statistically significant increases in the anagen ratio after several months of regular application." — Marks DH et al., American Journal of Clinical Dermatology, 2020
Visible change lags the biochemistry by months — a 12–16 week minimum is required before any photo-tracked response is meaningful, and the plateau sits around 9–12 months. Discontinuation reverses the gains within 3–6 months as the follicle resumes androgen-driven miniaturization, which means fluridil — like finasteride and minoxidil — is a lifetime commitment to keep what it grows.
Complementary Mechanism in a Hair Stack#
Fluridil's local AR-suppression mechanism is non-overlapping with the other two pillars of the standard hair stack:
| Compound | Mechanism | Site of action |
|---|---|---|
| Finasteride / dutasteride | 5α-reductase inhibition (lowers DHT synthesis) | Systemic |
| Minoxidil | K-ATP channel opening, vasodilation, anagen prolongation | Topical (follicle) |
| Fluridil | AR protein downregulation | Topical (follicle, in situ) |
Because the three act at different points in the androgen-follicle axis, layering is mechanistically rational — and is the dominant community pattern for users running AAS, where systemic DHT load is elevated and a topical AR-side defense becomes essential for protecting the hairline without compromising the cycle.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 1–2 ml | Once daily | Documented entry-level range |
| Mid | 2–2 ml | Once daily | Most commonly studied range |
| High | 2–2 ml | Once daily | 2 mL of 2% solution applied to a fully dry scalp at bedtime. Once-daily is the only frequency tested in controlled trials; higher frequency does not help and risks application to a still-damp scalp, which hydrolyzes the drug. Community-compounded 3–5% solutions exist; 6% was forearm-tolerance tested but never efficacy-tested; 10% is anecdotal only. |
Cycle length & outcomes
Documented cycle
12–52 weeks
Plateau after
36 wks
Cycle Length & Protocol#
Fluridil is not a "cycle" compound in the AAS sense — it's a topical AR suppressor that works only while it's being applied. Discontinuation reverses the gains within 3–6 months as the follicle resumes androgen-driven miniaturization. The "cycle" concept here means time to visible response and realistic application horizons, not on/off periods.
There is no loading phase, no taper, and no PCT. The molecule is hydrolyzed at the amide bond on contact with any aqueous environment and is undetectable in serum at any point during chronic dosing.
"Neither fluridil nor its hydrolytic product BP-34 could be detected in the serum at baseline or at any time during the 90-day treatment period with 2% fluridil applied topically." — Sovak et al., Dermatologic Surgery (2002)
Goal-Based Dosing Ladder#
| Goal | Cycle Length | Concentration / Volume |
|---|---|---|
| Early-stage AGA retention (Norwood 1–2) | 12+ weeks, then indefinite | 2% Eucapil, 2 mL nightly |
| Active shedding / stabilization (Norwood 2–3) | 6+ months, then indefinite | 2% Eucapil, 2 mL nightly |
| On-cycle AAS scalp defense | Duration of cycle + 8 weeks post | 2% Eucapil, 2 mL nightly |
| Add-on to existing fin + min stack | Indefinite | 2% Eucapil, 2 mL nightly |
| Female-pattern thinning (shaft thickness) | 9+ months | 2% Eucapil, 2 mL nightly |
| Community maximalist (advanced only) | Indefinite | 3–5% compounded, 1–2 mL nightly |
The 2% concentration is the only dose with controlled human trial data. Forearm tolerability was confirmed up to 6%, but efficacy above 2% has never been formally tested. Community-compounded 3–5% solutions exist in tressless circles; 10% reports are anecdotal and unsupported.
Onset & Response Timeline#
Fluridil operates on follicular timescales, not pharmacokinetic ones. The serum half-life of the intact molecule is ~6 hours, but that's irrelevant — the active is deposited intra-follicularly and the limiting variable is the hair cycle itself.
- Weeks 0–4: No visible change. Possible transient shed as miniaturizing follicles synchronize.
- Weeks 4–12: Reduced shedding becomes apparent. The pivotal trial documented anagen ratio shifts beginning here.
- Months 3–6: Phototrichogram-detectable anagen increase. Shaft thickness begins improving.
- Months 6–9: Visible thickening in responders. The female cohort's shaft-diameter gains plateaued around this point.
- Months 9–12: Maximum response. Anagen ratio in the pivotal trial shifted from ~76% (placebo) to ~89% (fluridil) by month 9.
"Fluridil has demonstrated efficacy in male pattern hair loss, with studies reporting statistically significant increases in the anagen ratio after several months of regular application." — Marks et al., American Journal of Clinical Dermatology (2020)
Users quitting at 3 months because "nothing happened" are the modal failure case. The 12-week mark is when retention becomes measurable, not when regrowth peaks.
Tapering, Loading & Bloodwork#
Loading: None. The follicle is either receiving the drug nightly or it isn't — there is no tissue depot to saturate.
Tapering: Not applicable. The molecule has no systemic exposure, no HPTA involvement, and no receptor desensitization to manage. Discontinuation is abrupt by design — the only consequence is the gradual return of androgen signalling at the follicle over the following 3–6 months.
Bloodwork: None required. The pivotal trial documented unchanged serum testosterone, unchanged hematology and chemistry panels, and no measurable fluridil or BP-34 in serum at day 0, 3, or 90 of daily application.
"Fluridil is a topically administered, non-steroidal antiandrogen that degrades rapidly after skin absorption, and clinical data suggest a favorable safety profile with no detectable systemic exposure." — Blumeyer et al., JDDG (2011)
The only meaningful endpoint is photographic tracking: same lighting, same angle (hairline, crown, vertex), monthly. Standardized phototrichograms are the clinical gold standard but impractical for at-home tracking; consistent photos under fixed conditions are good enough to catch a non-responder by month 6.
Application Protocol (the part that actually determines outcomes)#
The single largest determinant of fluridil response is application technique, not dose. The molecule is destroyed by water in minutes.
- Hair is washed and fully air-dried for at least 2 hours, or blow-dried completely. Damp scalp = no drug delivery.
- The 2 mL ampoule (or dropper-measured 2 mL of compounded solution) is applied directly to thinning areas at bedtime.
- The solution is worked into the scalp with fingertips, not rubbed vigorously.
- No washing, sweating heavily, or wetting the scalp for at least 4 hours afterwards.
- Co-applied topicals (minoxidil, RU58841) are spaced by ≥4 hours — minoxidil in the morning, fluridil at night is the standard sequence.
- Microneedling is performed on a fluridil-off night; same-day application stings and risks systemic absorption through a compromised barrier.
The pattern is once-daily, every night, indefinitely. Twice-daily provides no documented benefit and substantially raises the risk of applying to a scalp still damp from the previous dose.
Realistic expectations are the difference between a satisfied 12-month user and a quitter at month 4. Fluridil is a retention and modest-thickening compound, not a Norwood-reverser. Users who set this expectation correctly report some of the best safety-adjusted satisfaction in the topical AR category.
Risks & mistakes
Common (most users)#
The published trial data is notable for what it doesn't show — no libido changes, no erectile dysfunction, no serum testosterone shifts, no hematology or chemistry abnormalities over 9–12 months of nightly 2% application (Sovak 2002). The side effects that do appear are essentially all vehicle-related, not drug-related.
- Scalp dryness or mild flaking — driven by the anhydrous isopropanol vehicle, not fluridil itself. More common in winter or in users with already-dry skin. Mitigate by applying to a slightly cooler scalp (not immediately post-shower), shortening the rub-in time, or alternating with a vehicle-free night every 3–4 days if persistent.
- Transient stinging on application — minor and usually resolves within 30–60 seconds. If it persists, the scalp likely has microabrasions (from scratching, aggressive shampooing, or recent microneedling) and application should be deferred 24–48 h.
- Slight alcohol odor — cosmetic, dissipates within minutes of application. Apply at bedtime to avoid it.
- No regrowth in the first 8–12 weeks — not technically a side effect, but the #1 reason users quit prematurely. Fluridil is a retention compound; visible phototrichogram changes don't appear until ~3 months and plateau around 9–12 months (Seligson 2003). Photo-track monthly under consistent lighting.
Uncommon (dose-dependent or individual)#
- Isopropanol-vehicle irritation severe enough to discontinue — two of eleven subjects in the female open-label cohort withdrew for this reason (Seligson 2003). Sensitive-skin users can patch-test the inner forearm for 3 nights before committing to full scalp application.
- Contact dermatitis — rare, manifests as itching, redness, or persistent flaking beyond the first 2 weeks. If it appears, drop application frequency to every other night; if it persists, the vehicle (not the active) is the issue and switching to a community-compounded propylene-glycol-free formulation may help.
- Anecdotal libido reduction at very high concentrations (≥5%) — not seen in the controlled 2% trial, but reported sporadically on tressless among users running 5–10% community-compounded solutions. Mechanism speculative (trace systemic absorption overwhelming the hydrolysis sink). If suspected, drop back to 2% — that is the only concentration with controlled human safety data.
- Reduced efficacy in users who can't keep their scalp dry — not strictly a side effect but worth flagging as the most common protocol failure. Aqueous contact at the scalp hydrolyzes the amide bond before deposition.
"Neither fluridil nor its hydrolytic product BP-34 could be detected in the serum at baseline or at any time during the 90-day treatment period with 2% fluridil applied topically." — Sovak et al., Dermatologic Surgery 2002
Rare but serious#
Genuinely rare territory for this compound — the published clinical and preclinical work documents no serious adverse events at recommended concentrations.
- Allergic contact dermatitis with vesiculation or weeping — not documented in trials but theoretically possible with any topical. Discontinue immediately and the lesion typically resolves within 1–2 weeks. Patch-test before any rechallenge.
- Photosensitivity — preclinical work showed no phototoxicity or photoallergy (Seligson 2003), but isolated sensitivity in individual users cannot be ruled out. Application at bedtime mitigates UV exposure entirely.
- Signs warranting discontinuation: spreading rash beyond the scalp, persistent erythema lasting >72 h after a single application, or any systemic symptom (which would be biologically unexpected given the zero-absorption profile, and should prompt evaluation for an unrelated cause).
"Fluridil is a topically administered, non-steroidal antiandrogen that degrades rapidly after skin absorption, and clinical data suggest a favorable safety profile with no detectable systemic exposure." — Blumeyer et al., JDDG 2011
Hard contraindications#
- Damp scalp application — water hydrolyzes the amide bond and destroys the active before it can partition into the follicle. This is a protocol contraindication, not a safety one, but it's absolute: dry scalp or no application.
- Same-day post-microneedling application — broken stratum corneum bypasses the topical-only safety profile and exposes raw dermis to isopropanol. Space microneedling and fluridil by at least 24 h.
- Known isopropanol intolerance — the vehicle is non-negotiable in commercial Eucapil; raw-powder users would need to formulate in alternative anhydrous solvents (no validated protocols exist).
- Broken or actively inflamed scalp skin — defer application until the barrier has healed.
Gender, fertility, and PCT considerations#
Fluridil has no measurable systemic exposure, which makes it the cleanest compound in the topical-antiandrogen category for users with concerns the systemic 5-AR inhibitors create:
- PCT: not required. No HPTA suppression, no LH/FSH effects, no testosterone shifts documented over 90 days of daily application (Sovak 2002).
- Fertility / semen quality: no documented effects. This is a meaningful advantage over oral finasteride/dutasteride for users planning near-term conception — the AR suppression is confined to the scalp follicle.
- AAS stacking: no documented interaction. Fluridil can be layered onto any cycle (DHT-derivatives, 19-nors, trans-dermal testosterone) without systemic interference. This is why it earns a slot in on-cycle scalp-defense stacks where systemic 5-AR inhibition is contraindicated (e.g., nandrolone cycles where finasteride paradoxically worsens androgenic damage).
- Female users: the 11-subject open-label female cohort showed increased hair shaft thickness over 9 months at 2% nightly with no systemic exposure detected and no menstrual-cycle effects (Seligson 2003). The two withdrawals were vehicle-irritation, not drug-related. Data is thin but the safety profile makes it one of the more reasonable topical AR-active options for female users who cannot run oral antiandrogens.
- Pregnancy: with zero detectable systemic absorption, the teratogenicity concerns that apply to oral 5-AR inhibitors don't translate here. That said, no dedicated pregnancy data exists — defer use during pregnancy as a conservative default.
Bottom line: fluridil is, on the published evidence, the cleanest-tolerated compound in the topical AGA toolkit. The trade-off for that safety is modest absolute efficacy — set expectations for retention and mild thickening, not Norwood reversal, and the compound delivers on what it claims.
FAQ — Fluridil
Research & citations
5 studies cited on this page.
Conclusion
Fluridil stands out as the cleanest, best-tolerated topical AR suppressor for hair retention — especially for users prioritizing scalp-targeted action without systemic side effects. Its rapid inactivation systemically and hydrolytic instability in water make it exceptionally safe, with a protocol that even community maximalists struggle to break.
Key takeaways:
- Standard protocol: 2% fluridil in anhydrous isopropanol, 1–2 mL nightly, applied strictly to a dry scalp
- No detectable systemic absorption or endocrine disruption, even with years of daily application (Sovak 2002)
- Zero sexual or cognitive side effects in clinical studies; rare scalp irritation traced to the isopropanol vehicle
- Real-world results: significant increase in anagen ratio and hair shaft thickness, mainly retention rather than dramatic regrowth (Marks 2020)
- Stacks cleanly with minoxidil, microneedling, and oral/topical finasteride; application timing must avoid damp scalp and same-day microneedling
- Most appropriate for users refusing or sensitive to oral 5-AR inhibitors, or as a local-defense layer on AAS cycles where systemic inhibition is not an option
For anyone chasing minimal systemic risk and seamless stacking in an evidence-backed topical hair protocol, fluridil remains the gold-standard baseline for AR suppression on the scalp.